Abstract: The subject invention pertains to novel compounds, compositions containing the novel compounds, and methods for targeting gram-positive bacteria with the compounds or compositions of the subject invention. The subject invention further pertains to novel compounds, novel compositions, and methods for targeting gram-positive bacteria persister cells and gram-positive bacterial biofilms. The subject compounds and compositions can target gram-positive bacteria by modulating the proton motive force, calcium influx, autolysis, or any combination thereof. The novel compounds are synthetic, small molecules that can induce the death of gram-positive bacteria.

Abstract: The present disclosure provides a medical device (100) for electrical stimulation. The medical device (100) includes electric circuitry configured to perform active charge compensation, said electric circuitry being connectable to at least one electrode arrangement (102) for electrical stimulation. The electric circuitry includes monitoring means configured to monitor at least one voltage associated with a stimulation network (108, 116); at least one variable resistive element configured to provide an voltage drop used in the active charge compensation: and adjustment means configured to dynamically adjust a resistance value of the at least one variable resistive element during the active charge compensation based on the at least one monitored voltage, wherein the adjustment means (202) is a finite state machine for neurostimulation.

Abstract: The present disclosure relates to a pharmaceutical composition comprising: (a) ?-lactam antibiotics and (b) a metallo-?-lactamases (MBLs) inhibitor. The inhibitor relates to Bi(III) compounds or the pharmaceutically acceptable salts thereof. The present patent also provides methods of making Bi(III) compounds or the pharmaceutically acceptable salts thereof. Also provided is a method for treating MBLs-producing bacterial infection using a metal replacement mechanism.

Abstract: The present disclosure relates to a pharmaceutical composition comprising: (a) ?-lactam antibiotics and (b) a metallo-?-lactamases (MBLs) inhibitor. The inhibitor relates to Bi(III) compounds or the pharmaceutically acceptable salts thereof. The present patent also provides methods of making Bi(III) compounds or the pharmaceutically acceptable salts thereof. Also provided is a method for treating MBLs-producing bacterial infection using a metal replacement mechanism.

Abstract: The present invention provides a compound as shown in formula (I), formula (II), or formula (III), which can inhibit the binding of influenza virus PB2 protein to RNA cap and has an anti-influenza effect.

Abstract: The present disclosure relates to a pharmaceutical composition comprising: (a) ?-lactam antibiotics and (b) a metallo-?-lactamases (MBLs) inhibitor. The inhibitor relates to Bi(III) compounds or the pharmaceutically acceptable salts thereof. The present patent also provides methods of making Bi(III) compounds or the pharmaceutically acceptable salts thereof. Also provided is a method for treating MBLs-producing bacterial infection using a metal replacement mechanism.

Abstract: A cloud based collaborative work environment enables users to work collaboratively within a shared workspace. An application server on a host device is accessible to client devices via a communication network and maintains the shared workspace for collaboration between users. Client applications hosted on client devices enable users of the workspace to access and make changes in the shared workspace, such as adding or deleting items to or from the workspace, editing or annotating existing items, viewing items in the workspace, or downloading items in the workspace. Local copies of the shared workspace are maintained by the client devices and are synchronized with the shared workspace maintained by the application server so that any changes made to by a user to its local copy of the shared workspace are propagated to other users. Thus, synchronization is maintained between master workspace and the local workspaces on the client devices.

Abstract: The present disclosure relates to a pharmaceutical composition comprising: (a) ?-lactam antibiotics and (b) a metallo-?-lactamases (MBLs) inhibitor. The inhibitor relates to Bi(III) compounds or the pharmaceutically acceptable salts thereof. The present patent also provides methods of making Bi(III) compounds or the pharmaceutically acceptable salts thereof. Also provided is a method for treating MBLs-producing bacterial infection using a metal replacement mechanism.

Abstract: A network-based chat server provides a virtual chat room for chat participants, and synchronizes and shares chat dialogue exchanged between the chat participants regardless of whether the chat participants are logged onto the same chat platform or different chat platforms. The chat server includes a plurality of chat proxies; each of which is configured to communicate data with a particular chat platform. A chat synchronizer function executing at the chat server communicates the chat dialogue between the chat participants via the chat proxies.

Abstract: A cloud based collaborative work environment enables users to work collaboratively within a shared workspace. An application server on a host device is accessible to client devices via a communication network and maintains the shared workspace for collaboration between users. Client applications hosted on client devices enable users of the workspace to access and make changes in the shared workspace, such as adding or deleting items to or from the workspace, editing or annotating existing items, viewing items in the workspace, or downloading items in the workspace. Local copies of the shared workspace are maintained by the client devices and are synchronized with the shared workspace maintained by the application server so that any changes made to by a user to its local copy of the shared workspace are propagated to other users. Thus, synchronization is maintained between master workspace and the local workspaces on the client devices.

Abstract: An intraocular lens with a hydrophilic polymer coating composition and method of preparing same are provided. Specifically, a composition suitable for reducing tackiness in intraocular lenses is provided wherein an acrylic intraocular lens is treated by vapor deposition with an alkoxy silyl terminated polyethylene glycol polymer composition.

Abstract: An intraocular lens with a hydrophilic polymer coating composition and method of preparing same are provided. Specifically, a composition suitable for reducing tackiness in intraocular lenses is provided wherein an acrylic intraocular lens is treated by vapor deposition with an alkoxy silyl terminated polyethylene glycol polymer composition.

Abstract: This invention involves a plasma treated and controllable release antimicrobial peptide coated titanium alloy for surgical implantation, where the alloy with antimicrobial properties is fabricated using surface techniques without adversely compromising its biocompatibility and original mechanical properties. The surface techniques form antimicrobial layers on the alloy capable of resisting microbial adhesion and proliferation, while allowing mammalian cell adhesion and proliferation when the alloy is implanted to human body. In one embodiment, PIII&D is applied to incorporate ions, electrons, free radicals, atoms or molecules on a titanium alloy substrate. A pressurized hydrothermal treatment can be carried out to establish reactive functional groups for antimicrobial purpose or for connecting the substrate and external antimicrobial molecules.

Abstract: An intraocular lens with a hydrophilic polymer coating composition and method of preparing same are provided. Specifically, a composition suitable for reducing tackiness in intraocular lenses is provided wherein an acrylic intraocular lens is treated by vapor deposition with an alkoxy silyl terminated polyethylene glycol polymer composition.

Abstract: We have devised an apparatus useful for and a method of removing impurities from vaporous precursor compositions used to generate reactive precursor vapors from which thin films/layers are formed under sub-atmospheric conditions. The method is particularly useful when the layer deposition apparatus provides for precise addition of quantities of different combinations of reactants during a single step or when there are a number of different individual steps in the layer formation process, where the presence of impurities has a significant affect on both the quantity of reactants being charged and the overall composition of the reactant mixture from which the layer is deposited. The method is particularly useful when the vapor pressure of a liquid reactive precursor is less than about 250 Torr at atmospheric pressure.

Abstract: An improved vapor-phase deposition method and apparatus for the application of multilayered films/coatings on substrates is described. The method is used to deposit multilayered coatings where the thickness of an oxide-based layer in direct contact with a substrate is controlled as a function of the chemical composition of the substrate, whereby a subsequently deposited layer bonds better to the oxide-based layer. The improved method is used to deposit multilayered coatings where an oxide-based layer is deposited directly over a substrate and a SAM organic-based layer is directly deposited over the oxide-based layer. Typically a series of alternating layers of oxide-based layer and organic-based layer are applied.

Abstract: An improved vapor-phase deposition method and apparatus for the application of multilayered films/coatings on substrates is described. The method is used to deposit multilayered coatings where the thickness of an oxide-based layer in direct contact with a substrate is controlled as a function of the chemical composition of the substrate, whereby a subsequently deposited layer bonds better to the oxide-based layer. The improved method is used to deposit multilayered coatings where an oxide-based layer is deposited directly over a substrate and a SAM organic-based is directly deposited over the oxide-based layer. Typically a series of alternating layers of oxide-based layer and organic-based layer are applied.

Abstract: An improved vapor-phase deposition method and apparatus for the application of multilayered films/coatings on substrates is described. The method is used to deposit multilayered coatings where the thickness of an oxide-based layer in direct contact with a substrate is controlled as a function of the chemical composition of the substrate, whereby a subsequently deposited layer bonds better to the oxide-based layer. The improved method is used to deposit multilayered coatings where an oxide-based layer is deposited directly over a substrate and an organic-based layer is directly deposited over the oxide-based layer. Typically, a series of alternating layers of oxide-based layer and organic-based layer are applied.

Abstract: We have developed an improved vapor-phase deposition method and apparatus for the application of layers and coatings on various substrates. The method and apparatus are useful in the fabrication of biofunctional devices, Bio-MEMS devices, and in the fabrication of microfluidic devices for biological applications. In one important embodiment, oxide/polyethylene glycol coatings provide increased hydrophilicity and improved biocompatibility for medical devices and implants.